Please wait

 

tpb01.jpg

 

Turning Point Brands Announces Third Quarter 2025 Results

 

Consolidated Net Sales for Q3 2025 increased 31.2% year-over-year to $119.0 million

Modern Oral Net Sales for Q3 2025 increased 627.6% year-over-year to $36.7 million, accounting for 30.8% of total Company Net Sales

Q3 2025 Adjusted EBITDA of $31.3 million, up 17.2% over prior year

Company increasing 2025 Adjusted EBITDA guidance to $115.0  120.0 million (from $110.0  114.0 million)

Company increasing full-year Modern Oral sales guidance to $125.0  130.0 million (from $100.0  110.0 million)

 

LOUISVILLE, KY Nov 5, 2025 Turning Point Brands, Inc. (“TPB” or the “Company”) (NYSE: TPB), a manufacturer, marketer and distributor of branded consumer products, including alternative smoking accessories and consumables with active ingredients, today announced financial results for the third quarter ended September 30, 2025.

 

Q3 2025 vs. Q3 2024 

 

Total consolidated Net Sales increased 31.2% to $119.0 million

 

o

Stoker’s segment Net Sales increased 80.8% 

 

o

Zig-Zag segment Net Sales decreased 10.5% 

Gross Profit increased 39.7% to $70.4 million 

Net Income increased 70.3% to $21.1 million 

Adjusted EBITDA increased 17.2% to $31.3 million (see Schedule A for a reconciliation to net income) 

Adjusted Net Income increased 18.3% to $19.6 million (see Schedule B for a reconciliation to net income) 

Diluted EPS of $1.13 and Adjusted Diluted EPS of $1.27 compared to $0.68 and $0.91, respectively, in the same period one year ago (see Schedule B for a reconciliation to Diluted EPS)

Company raised $97.5 million of net proceeds at an average price of $98.59 per share under previously announced “At the Market” offering program; capital to be deployed across a variety of high return opportunities to accelerate growth of Modern Oral.

 

Graham Purdy, President and CEO, commented, “Our consolidated third quarter results exceeded expectations. Modern Oral sales were $36.7 million, increasing by 22% versus the prior quarter and 628% over the prior year. In addition, we now expect to qualify our first U.S. white pouch production lines in the first half of 2026.”

 

Stokers Products Segment (63% of total net sales in the quarter) 

 

For the third quarter, Stoker’s segment net sales increased 80.8% from the prior year to $74.8 million, driven by strong growth in Modern Oral sales, mid-single-digit growth in MST and low-single-digit growth in looseleaf.

 

Stoker’s segment gross profit increased 95.2% from the prior year and 3.5% sequentially to $45.0 million. Gross margin increased 440 basis points from the prior year to 60.2%.

 

 

 

Zig-Zag Products Segment (37% of total net sales in the quarter) 

 

For the third quarter, Zig-Zag segment net sales decreased 10.5% from the prior year and 6.1% sequentially to $44.2 million. Excluding the previously discussed wind-down of our Clipper business, Zig-Zag was up mid-single-digits sequentially, which slightly beat our expectations.

 

Zig-Zag segment gross profit decreased 7.1% from the prior year but increased 9.9% sequentially to $25.4 million. Gross margin increased 210 basis points from the prior year to 57.5%.

 

Performance Measures in the Third Quarter 

 

Third quarter 2025 consolidated selling, general and administrative (“SG&A”) expenses increased 50.5% from the prior year and 10.5% sequentially to $44.5 million, inclusive of increased Modern Oral-related sales and marketing investments and increased outbound freight costs.

 

Third quarter SG&A included the following notable items: 

 

$0.5 million of FDA PMTA-related expenses for Modern Oral products compared to $1.2 million in the prior year period; and

$0.8 million of transaction-related costs compared to $0.9 million in the prior year period.

 

Total gross debt as of September 30, 2025 was $300.0 million. Net debt (total gross debt less unrestricted cash) as of September 30, 2025 was $98.8 million. The Company ended the quarter with total liquidity of $267.8 million, comprised of $201.2 million in cash and $66.6 million of availability under an asset backed revolving credit facility.  

 

Consistent with the Company’s policy of maintaining active buyback and sales authorizations to maximize capital markets flexibility, the Company plans to amend its ATM prospectus supplement and buyback authorization to provide for $200 million of capacity under each program. There are no current plans to transact under the updated authorizations.

 

2025 Outlook 

 

The Company is increasing full-year 2025 Adjusted EBITDA guidance to $115.0 – 120.0 million (from $110.0 – 114.0 million) and projected full-year 2025 Modern Oral sales to $125.0 – 130.0 million (from $100.0 – 110.0 million).

 

Earnings Conference Call

 

As previously disclosed, a conference call with the investment community to review TPB’s financial results has been scheduled for 8:30 a.m. Eastern on Wednesday, November 5, 2025. Investment community participants should dial in 10 minutes ahead of time using the toll-free number (800) 715-9871 (international participants should call (646) 307-1963) and follow the audio prompts after typing in the event ID: 6640134. A live listen-only webcast of the call will be available on the Events and Presentations section of the investor relations portion of the Company website (www.turningpointbrands.com). A replay of the webcast will be available on the website two hours following the call. 

 

Non-GAAP Financial Measures 

 

In addition to financial measures prepared in accordance with generally accepted accounting principles in the United States (GAAP), this press release includes certain non-GAAP financial measures including EBITDA, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS and Adjusted Operating Income (Loss). A reconciliation of these non-GAAP financial measures accompanies this release.

 

2
Turning Point Brands, Inc. | www.turningpointbrands.com | ir@tpbi.com | 502.774.9238

 

 

About Turning Point Brands, Inc. 

 

Turning Point Brands (NYSE: TPB) is a manufacturer, marketer and distributor of branded consumer products including smoking accessories and consumables with active ingredients through its Zig-Zag®, Stoker’s®, FRE®, and Alp Pouch® brands. TPB’s products are available in more than 220,000 retail outlets in North America, and on sites such as www.zigzag.com. For the latest news and information about TPB and its brands, please visit www.turningpointbrands.com.

 

Forward-Looking Statements  

 

This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may generally be identified by the use of words such as "anticipate," "believe," "expect," "intend," "plan" and "will" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. As a result, these statements are not guarantees of future performance and actual events may differ materially from those expressed in or suggested by the forward-looking statements. Any forward-looking statement made by TPB in this press release, its reports filed with the Securities and Exchange Commission (the “SEC”) and other public statements made from time-to-time speak only as of the date made. New risks and uncertainties come up from time to time, and it is impossible for TPB to predict or identify all such events or how they may affect it. TPB has no obligation, and does not intend, to update any forward-looking statements after the date hereof, except as required by federal securities laws. Factors that could cause these differences include, but are not limited to, those included in the Company’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed by the Company with the SEC. These statements constitute the Company’s cautionary statements under the Private Securities Litigation Reform Act of 1995.  

 

This press release contains TPB’s preliminary determinations and current expectations, and such information is inherently uncertain. The preliminary estimates provided herein have been prepared by, and are the responsibility of, management and are subject to completion of TPB's customary quarter-end closing and review procedures and third-party review. As a result, TPB's reported information in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 may differ from this information, and any such differences may be material. In addition, the information furnished above does not include all of the information regarding TPB's financial condition and results of operations for the quarter ending September 30, 2025 that may be important to readers. As a result, readers are cautioned not to place undue reliance on the information furnished in this press release and should view this information in the context of TPB's full third quarter 2025 results when such results are disclosed by TPB in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.

 

Investor Contacts 

 

Turning Point Brands, Inc. 

ir@tpbi.com

 

 

Financial Statements Follow on Subsequent Pages

 

3
Turning Point Brands, Inc. | www.turningpointbrands.com | ir@tpbi.com | 502.774.9238

 

Turning Point Brands, Inc.

Consolidated Statements of Income

(dollars in thousands except share data)

(unaudited)

 

   

Three Months Ended September 30,

 
   

2025

   

2024

 
                 

Net sales

  $ 118,979     $ 90,704  

Cost of sales

    48,552       40,309  

Gross profit

    70,427       50,395  

Selling, general, and administrative expenses

    44,542       29,590  

Operating income

    25,885       20,805  

Other (income) expense, net

    (4,941 )     -  

Interest expense, net

    3,531       3,831  

Investment (gain) loss

    (817 )     (143 )

(Income) losses from equity method investment

    (2,117 )     (60 )

Income from continuing operations before income taxes

    30,229       17,177  

Income tax expense

    6,472       4,652  

Income from continuing operations

    23,757       12,525  

Loss from discontinued operations, net of tax

    -       (165 )

Consolidated net income

    23,757       12,360  

Net income (loss) attributable to non-controlling interest

    2,677       (16 )

Net income attributable to Turning Point Brands, Inc.

  $ 21,080     $ 12,376  
                 

Basic income per common share:

               

Continuing operations

  $ 1.16     $ 0.70  

Discontinued operations

    -       -  

Net income attributable to Turning Point Brands, Inc.

  $ 1.16     $ 0.70  

Diluted income per common share:

               

Continuing operations

  $ 1.13     $ 0.68  

Discontinued operations

    -       -  

Net income attributable to Turning Point Brands, Inc.

  $ 1.13     $ 0.68  

Weighted average common shares outstanding:

               

Basic

    18,246,722       17,722,855  

Diluted

    18,708,665       18,448,720  

 

4
Turning Point Brands, Inc. | www.turningpointbrands.com | ir@tpbi.com | 502.774.9238

 

Turning Point Brands, Inc.

Consolidated Balance Sheets

(dollars in thousands except share data)

 

   

(unaudited)

         
   

September 30,

   

December 31,

 
   

2025

   

2024

 
ASSETS                

Current assets:

               

Cash

  $ 201,189     $ 46,158  

Accounts receivable, net of allowances of $174 in 2025 and $66 in 2024

    27,792       9,624  

Inventories, net

    112,790       96,253  

Current assets held for sale

    -       11,470  

Other current assets

    54,665       34,700  

Total current assets

    396,436       198,205  

Property, plant, and equipment, net

    33,880       26,337  

Deferred tax assets, net

    -       995  

Right of use assets

    12,915       11,610  

Deferred financing costs, net

    1,341       1,823  

Goodwill

    136,068       135,932  

Other intangible assets, net

    64,344       65,254  

Master Settlement Agreement (MSA) escrow deposits

    29,762       28,676  

Noncurrent assets held for sale

    -       3,859  

Other assets

    68,102       20,662  

Total assets

  $ 742,848     $ 493,353  
                 

LIABILITIES AND STOCKHOLDERS' EQUITY

               

Current liabilities:

               

Accounts payable

  $ 24,599     $ 11,675  

Accrued liabilities

    46,738       31,096  

Current liabilities held for sale

    -       2,049  

Total current liabilities

    71,337       44,820  

Deferred tax liabilities, net

    3,971       -  

Notes payable and long-term debt

    293,364       248,604  

Other long-term liabilities

    6,182       -  

Lease liabilities

    9,841       9,549  

Total liabilities

  $ 384,695     $ 302,973  
                 

Commitments and contingencies

               
                 

Stockholders' equity:

               

Preferred stock, $0.01 par value; authorized shares 40,000,000; issued and outstanding shares -0-

    -       -  

Common stock, voting, $0.01 par value; authorized shares, 190,000,000; 20,527,900 issued shares and 19,070,757 outstanding shares at September 30, 2025, and 20,200,886 issued shares and 17,729,481 outstanding shares at December 31, 2024

    216       202  

Common stock, nonvoting, $0.01 par value; authorized shares, 10,000,000; issued and outstanding shares -0-

    -       -  

Additional paid-in capital

    200,376       126,662  

Cost of repurchased common stock (1,457,143 shares at September 30, 2025 and 2,471,405 shares at December 31, 2024)

    (47,637 )     (83,144 )

Accumulated other comprehensive loss

    (1,900 )     (2,903 )

Accumulated earnings

    192,895       147,164  

Non-controlling interest

    14,203       2,399  

Total stockholders' equity

    358,153       190,380  

Total liabilities and stockholders' equity

  $ 742,848     $ 493,353  

 

5
Turning Point Brands, Inc. | www.turningpointbrands.com | ir@tpbi.com | 502.774.9238

 

 

Turning Point Brands, Inc.

Consolidated Statements of Cash Flows

(dollars in thousands)

(unaudited)

 

   

Nine Months Ended September 30,

 
   

2025

   

2024

 

Cash flows from operating activities:

               

Consolidated net income

  $ 56,508     $ 37,459  

Loss from discontinued operations, net of tax

    -       208  

Adjustments to reconcile net income to net cash provided by operating activities:

               

Loss on extinguishment of debt

    1,235       -  

Loss on sale of property, plant, and equipment

    47       38  

Loss (gain) on investments

    (484 )     2,722  

(Income) losses from equity method investment

    (2,328 )     (217 )

Depreciation and other amortization expense

    4,489       3,182  

Amortization of other intangible assets

    918       913  

Amortization of deferred financing costs

    1,293       1,947  

Deferred income tax expense

    4,690       349  

Stock compensation expense

    5,176       5,720  

Noncash lease income

    (1,205 )     (317 )

Loss on MSA investments

    -       (14 )

Changes in operating assets and liabilities:

               

Accounts receivable

    (18,251 )     (447 )

Inventories

    (16,412 )     (8,149 )

Other current assets

    (19,409 )     1,422  

Other assets

    (10,978 )     (814 )

Accounts payable

    12,709       4,565  

Accrued liabilities and other

    14,517       (3,659 )

Operating cash flows from continuing operations

    32,515       44,908  

Operating cash flows from discontinued operations

    -       4,413  

Net cash provided by operating activities

  $ 32,515     $ 49,321  
                 

Cash flows from investing activities:

               

Capital expenditures

  $ (10,182 )   $ (3,516 )

Proceeds on the sale of property, plant and equipment

    -       3  

Payment for equity investments

    (2,783 )     -  

Purchases of investments

    (12,876 )     (8,865 )

Proceeds from sale of investments

    5,459       4,520  

Purchases of non-marketable equity investments

    -       (1,250 )

MSA escrow deposits, net

    (2 )     44  

Purchase of option agreement

    (8,000 )     -  

Investing cash flows from continuing operations

    (28,384 )     (9,064 )

Investing cash flows from discontinued operations

    -       -  

Net cash used in investing activities

  $ (28,384 )   $ (9,064 )
                 

Cash flows from financing activities:

               

Redemption of 2026 Notes

  $ (250,000 )   $ -  

Proceeds from 2032 Notes

    300,000       -  

At the market offering proceeds

    97,499       -  

Payment of Convertible Senior Notes

    -       (118,541 )

Interchange subscription agreement proceeds

    11,000       -  

Payment of dividends

    (4,089 )     (3,644 )

Payment of financing costs

    (7,285 )     (133 )

Exercise of options

    6,106       1,341  

Redemption of options

    (33 )     (328 )

Issuance of restricted stock units

    2       -  

Redemption of restricted stock units

    (2,324 )     (840 )

Issuance of performance based restricted stock units

    (1 )     -  

Redemption of performance based restricted stock units

    (2,625 )     (1,212 )

Common stock repurchased

    -       (4,170 )

Financing cash flows from continuing operations

    148,250       (127,527 )

Financing cash flows from discontinued operations

    -       -  

Net cash provided by (used in) financing activities

  $ 148,250     $ (127,527 )
                 

Net increase in cash

  $ 152,381     $ (87,270 )

Effect of foreign currency translation on cash

  $ (182 )   $ (29 )
                 

Cash, beginning of period:

               

Unrestricted

  $ 48,941     $ 117,886  

Restricted

    1,961       4,929  

Total cash at beginning of period

  $ 50,902     $ 122,815  
                 

Cash, end of period:

               

Unrestricted

  $ 201,189     $ 33,557  

Restricted

    1,912       1,959  

Total cash at end of period

  $ 203,101     $ 35,516  

 

6
Turning Point Brands, Inc. | www.turningpointbrands.com | ir@tpbi.com | 502.774.9238

 

Non-GAAP Financial Measures

 

To supplement our financial information presented in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, we use non-U.S. GAAP financial measures, including EBITDA, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS, and Adjusted Operating Income. We believe Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends relating to our financial condition and results of operations. Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS, and Adjusted Operating Income are used by management to compare our performance to that of prior periods for trend analyses and planning purposes and are presented to our board of directors. We believe that EBITDA, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS, and Adjusted Operating Income are appropriate measures of operating performance because they eliminate the impact of expenses that do not relate to business performance.

 

We define “EBITDA” as net income before interest expense, gain (loss) on extinguishment of debt, income tax expense, depreciation, amortization. We define “Adjusted EBITDA” as net income before interest expense, gain (loss) on extinguishment of debt, income tax expense, depreciation, amortization, other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted Net Income” as net income excluding items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted Diluted EPS” as diluted earnings per share excluding items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted Operating Income” as operating income excluding other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance.

 

Non-U.S. GAAP measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. EBITDA, Adjusted Net Income, Adjusted EBITDA, Adjusted Diluted EPS, and Adjusted Operating Income exclude significant expenses that are required by U.S. GAAP to be recorded in our financial statements and is subject to inherent limitations. In addition, other companies in our industry may calculate this non-U.S. GAAP measure differently than we do or may not calculate it at all, limiting its usefulness as a comparative measure.

 

In accordance with SEC rules, we have provided, in the supplemental information attached, a reconciliation of the non-GAAP measures to the next directly comparable GAAP measures.

 

7
Turning Point Brands, Inc. | www.turningpointbrands.com | ir@tpbi.com | 502.774.9238

 

Schedule A

 

Turning Point Brands, Inc.

Reconciliation of GAAP Net Income to Adjusted EBITDA

(dollars in thousands)

(unaudited)

   

Three Months Ended

 
   

September 30,

 
   

2025

   

2024

 

Net income attributable to Turning Point Brands, Inc.

  $ 21,080     $ 12,376  

Add:

               

Interest expense, net

    3,653       3,831  

Income tax expense

    6,694       4,652  

Depreciation expense

    814       943  

Amortization expense

    1,132       729  

EBITDA

  $ 33,373     $ 22,531  

Components of Adjusted EBITDA

               

Corporate restructuring (a)

    233       186  

ERP/CRM (b)

    -       154  

Stock based compensation (c)

    1,884       1,769  

Transactional expenses and strategic initiatives (d)

    820       873  

Non-recurring legal (e)

    437       -  

FDA PMTA (f)

    482       1,242  

Mark-to-market gain on Canadian inter-company note (g)

    (10 )     -  

Gain on investment (h)

    (678 )     -  

ERC refund (i)

    (5,451 )     -  

Honorarium (j)

    255       -  

Adjusted EBITDA

  $ 31,345     $ 26,755  

 


(a)  

Represents costs associated with corporate restructuring, including severance and early retirement.

(b)  

Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses.

(c)  

Represents non-cash stock options, restricted stock, PRSUs, etc.

(d)  

Represents the fees incurred for transaction expenses.

(e)

Represents legal expenses incurred in connection with litigation related to an insurance claim.

(f)

Represents costs associated with applications related to FDA premarket tobacco product application (“PMTA”). The PMTA regime requires the Company to submit an application to the FDA to receive marketing authorization to continue to sell certain of its product lines with continued sales permitted during the pendency of the applications. The application is a onetime resource-intensive process for each covered product line; however, due to the nature of the implementation process for those product lines already in the market, applications can take multiple years to complete rather than the typical one-time submission. The Company has only two product lines currently subject to the PMTA process, having utilized other regulatory pathway options available for our other product lines. The Company does not expect to submit additional PMTA applications for any new product lines after the submission for the remaining two are complete.

(g)

Represents a mark-to-market gain attributable to foreign exchange fluctuation.

(h)

Represents gain on investments.

(i)

Represents an employee retention credit refund received included in other (income) expense, net.

(j)

Represents an honorarium gift included in other (income) expense, net.

 

8
Turning Point Brands, Inc. | www.turningpointbrands.com | ir@tpbi.com | 502.774.9238

 

 

Schedule B

 

Turning Point Brands

Reconciliation of GAAP Net Income to Adjusted Net Income and Diluted EPS to Adjusted Diluted EPS

(dollars in thousands except share data)

(unaudited)

   

Three Months Ended

   

Three Months Ended

 
   

September 30, 2025

   

September 30, 2024

 
   

 

Income from

continuing

operations

before income

taxes

   

Income tax

expense (l)

   

 

Net income

attributable

to non-

controlling

interest

   

Net

Income

   

Diluted

EPS

   

Income from

continuing

operations

before

income taxes

   

Income

tax

expense (l)

   

Loss from

discontinued operations,

net of tax (m)

   

Net income

attributable

to non-

controlling

interest

   

Net

Income

   

Diluted

EPS

 

GAAP Net Income and Diluted EPS

  $ 30,229     $ 6,472     $ 2,677     $ 21,080     $ 1.13     $ 17,177     $ 4,652     $ 165     $ (16 )   $ 12,376     $ 0.68  

Loss on discontinued operations (a)

    -       -       -       -       -       -       -       (165 )     -       165       0.01  

Corporate restructuring (b)

    233       50       -       183       0.01       186       50       -       -       136       0.01  

ERP/CRM (c)

    -       -       -       -       -       154       42       -       -       112       0.01  

Stock based compensation (d)

    1,884       403       -       1,481       0.08       1,769       479       -       -       1,290       0.07  

Transactional expenses and strategic initiatives (e)

    820       176       -       644       0.03       873       236       -       -       637       0.03  

Non-recurring legal (f)

    437       94       -       343       0.02       -       -       -       -       -       -  

FDA PMTA (g)

    482       103       -       379       0.02       1,242       336       -       -       906       0.05  

Mark-to-market gain on Canadian inter-company note (h)

    (10 )     (2 )     -       (8 )     (0.00 )     -       -       -       -       -       -  

Gain on investment (i)

    (678 )     (145 )     -       (533 )     (0.03 )     -       -       -       -       -       -  

ERC refund (j)

    (5,451 )     (1,167 )     -       (4,284 )     (0.23 )     -       -       -       -       -       -  

Honorarium (k)

    255       55       -       200       0.01       -       -       -       -       -       -  

Tax benefit (l)

    -       (113 )     -       113       0.01       -       (952 )     -       -       952       0.05  

Adjusted Net Income and Adjusted Diluted EPS

  $ 28,201     $ 5,925     $ 2,677     $ 19,599     $ 1.05     $ 21,401     $ 4,844     $ -     $ (16 )   $ 16,573     $ 0.91  

Totals may not foot due to rounding

                                                 

 

(a)  

Represents loss on discontinued operations.

(b) 

Represents costs associated with corporate restructuring, including severance and early retirement.

(c) 

Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses.

(d)  

Represents non-cash stock options, restricted stock, PRSUs, etc.

(e)  

Represents the fees incurred for transaction expenses.

(f) 

Represents legal expenses incurred in connection with litigation related to an insurance claim.

(g)

Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA").  The PMTA regime requires the Company to submit an application to the FDA to receive marketing authorization to continue to sell certain of its product lines with continued sales permitted during the pendency of the applications. The application is a onetime resource-intensive process for each covered product line; however, due to the nature of the implementation process for those product lines already in the market, applications can take multiple years to complete rather than the typical one-time submission. The Company has only two product lines currently subject to the PMTA process, having utilized other regulatory pathway options available for our other product lines. The Company does not expect to submit additional PMTA applications for any new product lines after the submission for the remaining two are complete.

(h)

Represents a mark-to-market gain attributable to foreign exchange fluctuation.

(i)

Represents gain on option investment.

(j)

Represents an employee retention credit refund received included in other (income) expense, net.

(k)

Represents an honorarium gift included in other (income) expense, net.

(l)

Income tax expense calculated using the effective tax rate for the quarter of 21.4% in 2025 and 27.1% in 2024.

(m)

Tax allocation for discontinued operations excluded from adjusted net income.

 

9
Turning Point Brands, Inc. | www.turningpointbrands.com | ir@tpbi.com | 502.774.9238

 

Schedule C

 

Turning Point Brands, Inc.

Reconciliation of GAAP Operating Income to Adjusted Operating Income 

(dollars in thousands)

(unaudited)

   

Consolidated

   

Zig-Zag Products

   

Stoker's Products

 
   

3rd Quarter

   

3rd Quarter

   

3rd Quarter

   

3rd Quarter

   

3rd Quarter

   

3rd Quarter

 
   

2025

   

2024

   

2025

   

2024

   

2025

   

2024

 
                                                 

Net sales

  $ 118,979     $ 90,704     $ 44,154     $ 49,324     $ 74,825     $ 41,380  
                                                 

Gross profit

  $ 70,427     $ 50,395     $ 25,386     $ 27,324     $ 45,041     $ 23,071  
                                                 

Operating income

  $ 25,885     $ 20,805     $ 15,581     $ 17,378     $ 29,270     $ 17,162  

Adjustments:

                                               

Corporate restructuring

    233       186       -       -       -       -  

ERP/CRM

    -       154       -       -       -       -  

Transactional expenses and strategic initiatives

    820       873       -       -       -       -  

Non-recurring legal

    437       -                                  

FDA PMTA

    482       1,242       -       -       -       -  

Mark-to-market gain on Canadian inter-company note

    (10 )     -       -       -       -       -  

Adjusted operating income

  $ 27,847     $ 23,260     $ 15,581     $ 17,378     $ 29,270     $ 17,162  

 

10
Turning Point Brands, Inc. | www.turningpointbrands.com | ir@tpbi.com | 502.774.9238